NCT07769255Recruiting
Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine
Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine: A Randomized Controlled Trial Using Calcitonin Gene Related Peptide and Trigeminal Neurophysiological Biomarkers
Source: ClinicalTrials.gov · Last updated 17 Aug 2026
Brief summary (registry, in English)
Migraine is a debilitating neurological disorder characterized by recurrent headaches episodes, often accompanied by amplified perception of multiple sensory inputs such as cutaneous allodynia, photophobia, and phonophobia. The suggested mechanism in migraine is likely through sensitized trigeminovascular and dysfunctional pain modulatory systems. Dexmedetomidine, a selective α2-adrenergic receptor agonist, exerts central antinociceptive effects by reducing neuronal hyperexcitability, glial activation, and CGRP expression. Nebulized administration provides a non-invasive alternative to intravenous use, with rapid CNS absorption and minimal sedation .
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 146 (estimated)
- First submitted
- 12 Aug 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Mar 2027
- Lead sponsor
- Beni-Suef University
- Diseases
- Migraine
- NCT number
- NCT07769255
What you commit to
- Study type: Interventional
- Planned participants: 146
- From 1 Sept 2026 to the primary completion date, 1 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of sedatives, opioids, or CGRP-targeting therapies.
Other illness
- Presence of cardiopulmonary, psychiatric, or neurological comorbidities.
Other
- Pregnancy or breastfeeding.
Who the study is looking for
- Diagnosis of Early chronic migraine (\<6 months of ≥15 headache days/month), per ICHD-3 criteria.
- No preventive migraine therapy in the prior 8 weeks.
Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beni-Suef University Hospital Coordinator of this site? Confirm its status | Banī Suwayf | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.